Literature DB >> 21175437

Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.

Guangli Ma1, Lena E Friberg, Gunilla Movin-Osswald, Mats O Karlsson.   

Abstract

AIMS: The tolerance to the prolactin response following administration of antipsychotic drugs has been modelled as a depletion of a prolactin pool (pool model) and a model where the tolerance is explained by a feedback loop including the dopamine interaction of prolactin release (agonist-antagonist interaction model, (AAI model)). The AAI model was superior to the pool model when analyzing data from clinical trials of risperidone and paliperidone. Here we evaluated the two models using the remoxipride data, designed to challenge the short-term prolactin response, from which the original pool model was built.
METHODS: The remoxipride data were collected from a study where eight healthy male subjects received two remoxipride infusions on five occasions. The intervals between the first and second dose on each occasion were 2, 8, 12, 24 and 48 h, respectively. The pool and AAI models were fitted using NONMEM.
RESULTS: According to the objective function values the pool model with a circadian rhythm function fitted the data slightly better, while the AAI model was better in describing the circadian rhythm of prolactin. Visual predictive checks revealed that the models predicted the prolactin profiles equally well.
CONCLUSIONS: According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time.
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175437      PMCID: PMC3014065          DOI: 10.1111/j.1365-2125.2010.03758.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.

Authors:  P Francheteau; J L Steimer; C Dubray; D Lavene
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

Review 2.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

3.  Remoxipride: pharmacokinetics and effect on plasma prolactin.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

4.  Twenty-four-hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts.

Authors:  J D Veldhuis; A Iranmanesh; M L Johnson; G Lizarralde
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

Review 5.  Prolactin: structure, function, and regulation of secretion.

Authors:  M E Freeman; B Kanyicska; A Lerant; G Nagy
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

6.  Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

Authors:  N Mohell; M Sällemark; S Rosqvist; A Malmberg; T Högberg; D M Jackson
Journal:  Eur J Pharmacol       Date:  1993-07-06       Impact factor: 4.432

7.  Metabolic clearance and production rates of prolactin in man.

Authors:  D S Cooper; E C Ridgway; B Kliman; R N Kjellberg; F Maloof
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

8.  In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.

Authors:  J E Leysen; P M Janssen; W Gommeren; J Wynants; P J Pauwels; P A Janssen
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

9.  An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.

Authors:  L E Friberg; A M Vermeulen; K J F Petersson; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2008-12-24       Impact factor: 6.875

10.  Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.

Authors:  L Farde; C von Bahr
Journal:  Acta Psychiatr Scand Suppl       Date:  1990
View more
  7 in total

1.  Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.

Authors:  Akihide Wakamatsu; Kazuo Aoki; Yojiro Sakiyama; Takashi Ohnishi; Makoto Sugita
Journal:  Innov Clin Neurosci       Date:  2013-03

2.  Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.

Authors:  Willem J van den Brink; Yin C Wong; Berfin Gülave; Piet H van der Graaf; Elizatbeth C M de Lange
Journal:  AAPS J       Date:  2016-10-26       Impact factor: 4.009

3.  Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.

Authors:  Klas J Petersson; An M Vermeulen; Lena E Friberg
Journal:  AAPS J       Date:  2013-02-08       Impact factor: 4.009

4.  Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.

Authors:  Jasper Stevens; Bart A Ploeger; Margareta Hammarlund-Udenaes; Gunilla Osswald; Piet H van der Graaf; Meindert Danhof; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-12       Impact factor: 2.745

5.  A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.

Authors:  Michiel J van Esdonk; Jacobus Burggraaf; Piet H van der Graaf; Jasper Stevens
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-11       Impact factor: 2.745

6.  Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

Authors:  Amit Taneja; An Vermeulen; Dymphy R H Huntjens; Meindert Danhof; Elizabeth C M De Lange; Johannes H Proost
Journal:  Pharmacol Res Perspect       Date:  2017-12

7.  Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling.

Authors:  Michiel J van Esdonk; Jacobus Burggraaf; Marion Dehez; Piet H van der Graaf; Jasper Stevens
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-04-04       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.